Activation of Toll-Like Receptors and Inflammasome Complexes in the Diabetic Cardiomyopathy-Associated Inflammation
暂无分享,去创建一个
J. Egido | Ó. Lorenzo | J. Tuñón | J. Fuentes-Antrás | A. M. Ioan | J. Tuñón | J. Egido | Ó. Lorenzo | J. Fuentes-Antrás | A. Ioan | Ó. Lorenzo | Jesús Egido
[1] J. Egido,et al. Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes , 2013, Cardiovascular Diabetology.
[2] J. Egido,et al. Alteration of Energy Substrates and ROS Production in Diabetic Cardiomyopathy , 2013, Mediators of inflammation.
[3] E. Barroso,et al. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. , 2013, International journal of cardiology.
[4] T. Suuronen,et al. Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders. , 2013, Cellular signalling.
[5] M. Czech,et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes , 2013, Nature Medicine.
[6] M. Mattson,et al. Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke , 2013, Cell Death and Disease.
[7] R. Flavell,et al. Innate sensors of pathogen and stress: linking inflammation to obesity. , 2013, The Journal of allergy and clinical immunology.
[8] Ting-I Lee,et al. Peroxisome proliferator-activated receptors modulate cardiac dysfunction in diabetic cardiomyopathy. , 2013, Diabetes research and clinical practice.
[9] E. Latz,et al. Activation and regulation of the inflammasomes , 2013, Nature Reviews Immunology.
[10] M. Gillum,et al. Sirtuin-1 is a nutrient-dependent modulator of inflammation , 2013, Adipocyte.
[11] Kan Yang,et al. Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy , 2013, Cardiovascular Diabetology.
[12] H. Duff,et al. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin‐1β , 2013, Experimental physiology.
[13] S. Vogel,et al. Inhibition of TLR4 Signaling by TRAM-Derived Decoy Peptides In Vitro and In Vivo , 2013, The Journal of Immunology.
[14] C. Thiemermann,et al. Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR-δ agonism correlates with impaired NLRP3 inflammasome activation. , 2013, Biochemical pharmacology.
[15] L. Palmqvist,et al. Reduced expression of NLRP3 and MEFV in human ischemic heart tissue. , 2013, Biochemical and biophysical research communications.
[16] M. Rossol,et al. Extracellular Ca2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors , 2012, Nature Communications.
[17] R. Germain,et al. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP , 2012, Nature.
[18] M. Farkouh,et al. Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. , 2012, American heart journal.
[19] V. Dixit,et al. Phosphorylation of NLRC4 is critical for inflammasome activation , 2012, Nature.
[20] Anna K Rieger,et al. NLRP3 Inflammasome Activity Is Negatively Controlled by miR-223 , 2012, The Journal of Immunology.
[21] Y. Huang,et al. TLR4 regulates cardiac lipid accumulation and diabetic heart disease in the nonobese diabetic mouse model of type 1 diabetes. , 2012, American journal of physiology. Heart and circulatory physiology.
[22] E. Alnemri,et al. Non-transcriptional Priming and Deubiquitination Regulate NLRP3 Inflammasome Activation* , 2012, The Journal of Biological Chemistry.
[23] J. Tamargo,et al. Activation of peroxisome proliferator-activated receptor-β/-δ (PPARβ/δ) prevents endothelial dysfunction in type 1 diabetic rats. , 2012, Free radical biology & medicine.
[24] C. Zuurbier,et al. Deletion of the Innate Immune NLRP3 Receptor Abolishes Cardiac Ischemic Preconditioning and Is Associated with Decreased Il-6/STAT3 Signaling , 2012, PloS one.
[25] M. Lindsey,et al. Toll-Like Receptor (TLR) 2 and TLR4 Differentially Regulate Doxorubicin Induced Cardiomyopathy in Mice , 2012, PloS one.
[26] W. Wahli,et al. PPARs at the crossroads of lipid signaling and inflammation , 2012, Trends in Endocrinology & Metabolism.
[27] W. Hoffmann,et al. Variants of Toll-like Receptor 4 Predict Cardiac Recovery in Patients with Dilated Cardiomyopathy* , 2012, The Journal of Biological Chemistry.
[28] Y. Horio,et al. Emerging beneficial roles of sirtuins in heart failure , 2012, Basic Research in Cardiology.
[29] X. Dong,et al. Sirtuin biology and relevance to diabetes treatment. , 2012, Diabetes management.
[30] M. Fredrikson,et al. The Q705K Polymorphism in NLRP3 Is a Gain-of-Function Alteration Leading to Excessive Interleukin-1β and IL-18 Production , 2012, PloS one.
[31] Jianni Qi,et al. TLR‐induced NF‐κB activation regulates NLRP3 expression in murine macrophages , 2012, FEBS letters.
[32] Haitao Wen,et al. A role for the NLRP3 inflammasome in metabolic diseases—did Warburg miss inflammation? , 2012, Nature Immunology.
[33] Moshe Arditi,et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. , 2012, Immunity.
[34] A. Ortiz,et al. Proteome changes in the myocardium of experimental chronic diabetes and hypertension: role of PPARα in the associated hypertrophy. , 2012, Journal of proteomics.
[35] J. Brandão-Neto,et al. Increased TLR2 expression in patients with type 1 diabetes: evidenced risk of microalbuminuria , 2012, Pediatric diabetes.
[36] R. Isseroff,et al. Toll-like receptors and diabetes: a therapeutic perspective. , 2012, Clinical science.
[37] R. Savani,et al. Toll-like receptors, the NLRP3 inflammasome, and interleukin-1β in the development and progression of type 1 diabetes , 2012, Pediatric Research.
[38] A. Rosenzweig,et al. The fire within: cardiac inflammatory signaling in health and disease. , 2012, Circulation research.
[39] Ying He,et al. Sirtuin 1–Mediated Cellular Metabolic Memory of High Glucose Via the LKB1/AMPK/ROS Pathway and Therapeutic Effects of Metformin , 2011, Diabetes.
[40] T. Peng,et al. MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. , 2011, Cardiovascular research.
[41] F. Pashkow. Oxidative Stress and Inflammation in Heart Disease: Do Antioxidants Have a Role in Treatment and/or Prevention? , 2011, International journal of inflammation.
[42] M. Lopes-Virella,et al. DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice , 2011, Journal of cardiovascular pharmacology.
[43] P. Knuefermann,et al. The toll‐like receptor 4‐antagonist eritoran reduces murine cardiac hypertrophy , 2011, European journal of heart failure.
[44] J. Egido,et al. Potential Role of Nuclear Factor κB in Diabetic Cardiomyopathy , 2011, Mediators of inflammation.
[45] Denis Gris,et al. Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signaling , 2011, Nature Immunology.
[46] F. Pattou,et al. PPARβ/δ activation induces enteroendocrine L cell GLP-1 production. , 2011, Gastroenterology.
[47] A. Choi,et al. Dampening insulin signaling by an NLRP3 'meta-flammasome' , 2011, Nature Immunology.
[48] F. Villarroya,et al. Sirt1 acts in association with PPARα to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. , 2011, Cardiovascular research.
[49] P. Elliott,et al. Meta-Analysis of Genome-Wide Association Studies in >80 000 Subjects Identifies Multiple Loci for C-Reactive Protein Levels , 2011, Circulation.
[50] T. Noda,et al. Inflammasome Activation of Cardiac Fibroblasts Is Essential for Myocardial Ischemia/Reperfusion Injury , 2011, Circulation.
[51] W. Wahli,et al. PPARβ/δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. , 2011, Biochimica et biophysica acta.
[52] D. Charnock-Jones,et al. Developmental control of the Nlrp6 inflammasome and a substrate, IL-18, in mammalian intestine. , 2011, American journal of physiology. Gastrointestinal and liver physiology.
[53] Z. Shan,et al. Hyperglycemic Myocardial Damage Is Mediated by Proinflammatory Cytokine: Macrophage Migration Inhibitory Factor , 2011, PloS one.
[54] C. McCall,et al. NAD+-dependent SIRT1 Deacetylase Participates in Epigenetic Reprogramming during Endotoxin Tolerance* , 2011, The Journal of Biological Chemistry.
[55] N. Tsuchimori,et al. TAK-242 (Resatorvid), a Small-Molecule Inhibitor of Toll-Like Receptor (TLR) 4 Signaling, Binds Selectively to TLR4 and Interferes with Interactions between TLR4 and Its Adaptor Molecules , 2011, Molecular Pharmacology.
[56] S. Prabhu,et al. Cardiomyocyte NF-κB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. , 2011, Cardiovascular research.
[57] Xiaoshu Cheng,et al. Prevention of hyperglycemia-induced myocardial apoptosis by gene silencing of Toll-like receptor-4 , 2010, Journal of Translational Medicine.
[58] M. McDermott,et al. Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. , 2010, Current opinion in molecular therapeutics.
[59] L. Joosten,et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. , 2010, Cell metabolism.
[60] C. Glass,et al. ATVB in Focus Nuclear Receptors in Metabolism and Cardiovascular Disease , 2010 .
[61] L. O’Neill,et al. New Insights into the Regulation of Signalling by Toll-Like Receptors and Nod-Like Receptors , 2010, Journal of Innate Immunity.
[62] J. Kieswich,et al. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. , 2010, The Journal of endocrinology.
[63] J. Olefsky,et al. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. , 2010, American journal of physiology. Endocrinology and metabolism.
[64] J. Tschopp,et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation , 2010, Nature Immunology.
[65] Kate Schroder,et al. The NLRP3 Inflammasome: A Sensor for Metabolic Danger? , 2010, Science.
[66] S. Devaraj,et al. Increased Toll-Like Receptor (TLR) Activation and TLR Ligands in Recently Diagnosed Type 2 Diabetic Subjects , 2010, Diabetes Care.
[67] P. Doevendans,et al. Myocardial Ischemia / Reperfusion Injury Is Mediated by Leukocytic Toll-Like Receptor-2 and Reduced by Systemic Administration of a Novel Anti – Toll-Like Receptor-2 Antibody , 2009 .
[68] A. Sanz,et al. Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes. , 2009, American journal of physiology. Heart and circulatory physiology.
[69] V. Dixit,et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome , 2009, The Journal of cell biology.
[70] M. Fessler,et al. Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome , 2009, Current opinion in lipidology.
[71] M. Holness,et al. The role of PPARs in modulating cardiac metabolism in diabetes. , 2009, Pharmacological research.
[72] K. E. Jones,et al. Nutrient Stress Activates Inflammation and Reduces Glucose Metabolism by Suppressing AMP-Activated Protein Kinase in the Heart , 2009, Diabetes.
[73] T. Matsuo,et al. Roles of TLR2, TLR4, NOD2, and NOD1 in Pulp Fibroblasts , 2009, Journal of dental research.
[74] S. Devaraj,et al. Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. , 2009, Endocrinology.
[75] I. Karakikes,et al. Gene Remodeling in Type 2 Diabetic Cardiomyopathy and Its Phenotypic Rescue with SERCA2a , 2009, PloS one.
[76] E. Alnemri,et al. Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression1 , 2009, The Journal of Immunology.
[77] Jie Huang,et al. The IκBα gene is a peroxisome proliferator‐activated receptor cardiac target gene , 2009, The FEBS journal.
[78] R. Cooksey,et al. Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. , 2009, Cardiovascular research.
[79] Hong Jiang,et al. Valsartan preconditioning protects against myocardial ischemia–reperfusion injury through TLR4/NF-κB signaling pathway , 2009, Molecular and Cellular Biochemistry.
[80] P. Sritara,et al. Atorvastatin attenuates TLR4-mediated NF-kappaB activation in a MyD88-dependent pathway. , 2009, Asian Pacific journal of allergy and immunology.
[81] C. Buechler,et al. Fatty acid‐induced induction of Toll‐like receptor‐4/nuclear factor‐κB pathway in adipocytes links nutritional signalling with innate immunity , 2009, Immunology.
[82] C. Zhang,et al. Effects and mechanisms of PPARα activator fenofibrate on myocardial remodelling in hypertension , 2008, Journal of cellular and molecular medicine.
[83] T. Chan,et al. TNF- a reduces PGC-1 a expression through NF- k B and p38 MAPK leading to increased glucose oxidation in a human cardiac cell model , 2009 .
[84] D. White,et al. MOLECULAR OR PHARMACOLOGIC INHIBITION OF THE CD14 SIGNALING PATHWAY PROTECTS AGAINST BURN-RELATED MYOCARDIAL INFLAMMATION AND DYSFUNCTION , 2008, Shock.
[85] W. Wahli,et al. Activation of Peroxisome Proliferator–Activated Receptor β/δ Inhibits Lipopolysaccharide-Induced Cytokine Production in Adipocytes by Lowering Nuclear Factor-κB Activity via Extracellular Signal–Related Kinase 1/2 , 2008, Diabetes.
[86] P. Pfluger,et al. Sirt1 protects against high-fat diet-induced metabolic damage , 2008, Proceedings of the National Academy of Sciences.
[87] R. DeFronzo,et al. Elevated Toll-Like Receptor 4 Expression and Signaling in Muscle From Insulin-Resistant Subjects , 2008, Diabetes.
[88] G. Ertl,et al. Toll-like receptor signaling in the ischemic heart. , 2008, Frontiers in bioscience : a journal and virtual library.
[89] Toshiyuki Takahashi. Toll-like receptors and myocardial contractile dysfunction. , 2008, Cardiovascular research.
[90] P. Söderkvist,et al. Gene polymorphisms in the NALP3 inflammasome are associated with interleukin-1 production and severe inflammation: relation to common inflammatory diseases? , 2008, Arthritis and rheumatism.
[91] P. Poole‐Wilson,et al. Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure. , 2008, International journal of cardiology.
[92] Xianlin Han,et al. Nuclear receptors PPARβ/δ and PPARα direct distinct metabolic regulatory programs in the mouse heart , 2007 .
[93] M. Racke,et al. Peroxisome proliferator‐activated receptor‐α agonist fenofibrate regulates IL‐12 family cytokine expression in the CNS: relevance to multiple sclerosis , 2007, Journal of neurochemistry.
[94] Amy V. Lynch,et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes , 2007, Nature.
[95] J. Plutzky,et al. PPARα in atherosclerosis and inflammation , 2007 .
[96] S. Malozowski,et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. , 2007, The New England journal of medicine.
[97] C. Tschöpe,et al. Cardioprotective and Anti-Inflammatory Effects of Interleukin Converting Enzyme Inhibition in Experimental Diabetic Cardiomyopathy , 2007, Diabetes.
[98] E. Abel,et al. Diabetic cardiomyopathy revisited. , 2007, Circulation.
[99] S. Vatner,et al. Sirt1 Regulates Aging and Resistance to Oxidative Stress in the Heart , 2007, Circulation research.
[100] F. Martinon,et al. Inflammasome Components NALP 1 and 3 Show Distinct but Separate Expression Profiles in Human Tissues Suggesting a Site-specific Role in the Inflammatory Response , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[101] R. Caprioli,et al. Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. , 2007, Journal of molecular and cellular cardiology.
[102] M. Lohse,et al. A Role for Caspase-1 in Heart Failure , 2007, Circulation research.
[103] S. Anker,et al. Contributions of Inflammation and Cardiac Matrix Metalloproteinase Activity to Cardiac Failure in Diabetic Cardiomyopathy , 2007, Diabetes.
[104] L. Gan,et al. Parallel gene expressions of IL-6 and BNP during cardiac hypertrophy complicated with diastolic dysfunction in spontaneously hypertensive rats. , 2007, International journal of cardiology.
[105] K. Walley,et al. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. , 2006, Cardiovascular research.
[106] J. Flier,et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. , 2006, The Journal of clinical investigation.
[107] E. Verrier,et al. Inhibition of Toll-like Receptor 4 With Eritoran Attenuates Myocardial Ischemia-Reperfusion Injury , 2006, Circulation.
[108] H. Grafenstein,et al. Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse. , 2006, International immunology.
[109] I. Komuro,et al. [Molecular mechanisms of congestive heart failure]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.
[110] S. Akira,et al. TLR signaling. , 2006, Current topics in microbiology and immunology.
[111] R. DePinho,et al. The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin , 2005, Science.
[112] H. Methe,et al. Expansion of Circulating Toll-Like Receptor 4–Positive Monocytes in Patients With Acute Coronary Syndrome , 2005, Circulation.
[113] B. Horne,et al. Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. , 2004, American heart journal.
[114] W. Wahli,et al. PPARs as drug targets to modulate inflammatory responses? , 2004, Current drug targets. Inflammation and allergy.
[115] M. Tsan,et al. Endogenous ligands of Toll‐like receptors , 2004, Journal of leukocyte biology.
[116] Thomas H Marwick,et al. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. , 2004, Endocrine reviews.
[117] M. Mayo,et al. Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase , 2004, The EMBO journal.
[118] Douglas L Mann,et al. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. , 2002, Circulation research.
[119] H. Taegtmeyer,et al. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. , 2002, Circulation.
[120] S. Frantz,et al. Role of TLR-2 in the Activation of Nuclear Factor κB by Oxidative Stress in Cardiac Myocytes* , 2001, The Journal of Biological Chemistry.
[121] W. Kannel,et al. Role of diabetes in congestive heart failure: the Framingham study. , 1974, The American journal of cardiology.
[122] A. Grishman,et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. , 1972, The American journal of cardiology.